Register Now

Cipla shares see profit booking after Eli Lilly deal to market weight-loss drug in India

Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could clock FY26/FY27 sales of ₹360-370 crore while gaining a lead in the semaglutide opportunity.

Leave a Reply

Your email address will not be published. Required fields are marked *